The year-long study examined the effect of using Glytec’s Glucommander IV insulin treatment system on 35 patients seen in the ED with hyperglycemic crises and diagnosed with mild diabetic ketoacidosis.
Ultimately, the study found hospital admissions for mild DKA declined 45 percent after implementing the cloud-based system.
Co-author of the study Joseph Aloi, MD, chief of endocrinology and metabolism at Wake Forest School of Medicine in Winston-Salem, N.C., estimates to the cost savings associated with the reduction in admissions was $78,000.
More articles on care quality:
New American College of Radiology committee to focus on quality, patient safety
Improving outcomes with evidence-based guidelines at the point-of-care
Three interventions proven to reduce adverse drug events
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
